dc.contributor.author |
Malamos, N |
en |
dc.contributor.author |
Papadiamantis, I |
en |
dc.contributor.author |
Andonopoulos, M |
en |
dc.contributor.author |
Tsikkinis, A |
en |
dc.contributor.author |
Kosmas, H |
en |
dc.contributor.author |
Pallis, L |
en |
dc.contributor.author |
Kouri, E |
en |
dc.contributor.author |
Sfikas, K |
en |
dc.contributor.author |
Vassilaros, S |
en |
dc.date.accessioned |
2014-06-06T06:43:30Z |
|
dc.date.available |
2014-06-06T06:43:30Z |
|
dc.date.issued |
1998 |
en |
dc.identifier.uri |
http://dx.doi.org/10.1016/S0959-8049(98)80051-8 |
en |
dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/1322 |
|
dc.subject |
Randomised Clinical Trial |
en |
dc.subject |
Breast Cancer |
en |
dc.title |
A randomised clinical trial of primary chemotherapy (PC) with taxol + epirubicin (TE) V. 5FU + epirubicin + cyclophosphamide (FEC) in stage III A breast cancer: A preliminary report |
en |
heal.type |
journalArticle |
en |
heal.identifier.primary |
10.1016/S0959-8049(98)80051-8 |
en |
heal.publicationDate |
1998 |
en |
heal.journalName |
European Journal of Cancer |
en |
dc.identifier.doi |
10.1016/S0959-8049(98)80051-8 |
en |